Bayer, a global leader in women’s healthcare, has completed the acquisition of UK-based biotech company KaNDy Therapeutics Ltd. With this acquisition, Bayer plans to expand its drug development pipeline in women’s healthcare.
Bayer is a recognized leader in the area of women’s healthcare, with a commitment to delivering science for a better life by advancing a portfolio of innovative treatments.
Under the terms of the agreement, Bayer will pay upfront $425 million, followed by a potential milestone payment of up to $450 million until launch. This will be followed by additional triple-digit million sales milestone payments.
“We are pleased that with the antitrust clearance the closing of the acquisition has now been achieved,” said Stefan Oelrich, Member of the Board of Management of Bayer and President Pharmaceuticals